Q32 Bio Inc
$ 12.70
-1.32%
11 Jun - close price
- Market Cap 218,229,000 USD
- Current Price $ 12.70
- High / Low $ 13.14 / 12.29
- Stock P/E 4.28
- Book Value 3.17
- EPS 3.01
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 1.57 %
- 52 Week High 14.85
- 52 Week Low 1.34
About
Q32 Bio Inc. (QTTB) is an innovative biotechnology company specializing in the development of cutting-edge antibody-based therapies aimed at treating autoimmune diseases and optimizing immune responses. With its proprietary technology platform, Q32 Bio is advancing a diverse pipeline of therapeutic candidates poised to restore immune balance and address critical unmet medical needs. Supported by a highly experienced management team and strategic partnerships, Q32 Bio is strategically positioned to drive meaningful advancements in healthcare, ultimately creating long-term value for shareholders through its commitment to ongoing research and development excellence.
Analyst Target Price
$14.25
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTTB
2026-06-12 13:39:41
Q32 Bio Inc. (QTTB) stockholders approved all proposals at their Annual General Meeting, including director elections, audit firm ratification, and executive compensation. The voting results will be officially recorded in the company's minutes and SEC filings. This summary is AI-generated and should be verified with the original source.
2026-06-08 15:09:50
Q32 Bio's stock (QTTB) fell significantly, nearly 13.9% in morning trading, primarily due to dilution from recent equity financing transactions. A $55 million private placement at a discounted price of $8.00 per share and an active at-the-market offering program are pressuring the stock. Despite positive analyst sentiment, the lack of immediate pipeline catalysts and the stock's previous surge from its lows have created conditions for this sharp pullback, independent of the broader market's positive performance.
2026-06-08 08:09:50
Q32 Bio Inc., a clinical-stage biotechnology company, has successfully closed a $55 million private placement. Goodwin Procter LLP advised Q32 Bio, while WilmerHale advised the placement agents in this transaction. Full access to the details requires a standard membership.
2026-06-06 21:39:21
Q32 Bio has announced a private placement that is expected to generate $55 million in gross proceeds. This funding will be used to further develop its pipeline, particularly its leading product candidate, bempikinus alfa, which is currently undergoing evaluation for alopecia areata. The company aims to report topline results from the Phase 2 trial of bempikinus alfa in the second half of 2026.
2026-06-05 18:09:51
A group of affiliated entities led by Biotechnology Value Fund, L.P. (BVF Group) has reported a coordinated ownership in Q32 Bio Inc. (QTTB) through a Schedule 13G filing. The group collectively holds 2,367,524 shares and 150,000 pre-funded warrants, with an ownership limit of 9.99% restricting immediate warrant exercises to 17,524 shares as of June 4, 2026. This disclosure details the beneficial ownership percentages and the various entities within the BVF Group.
2026-06-05 07:09:00
Affiliates of RA Capital Management have disclosed a beneficial ownership of 2,332,457 shares, representing 9.8% of Q32 Bio (QTTB) common stock, according to a Schedule 13G SEC filing. This percentage calculation includes shares outstanding as of May 1, 2026, and additional shares issued in a private placement on May 28, 2026. RA Capital Healthcare Fund, L.P. directly holds these shares, with voting and dispositive authority delegated to RA Capital, though the reporting persons disclaim beneficial ownership except for Section 13(d) reporting responsibilities.
